Breast Recurrence Score Test Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Breast Recurrence Score Test Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global breast recurrence score test market reported revenue of $250 million in 2024 and is expected to reach a valuation of $510 million by the end of 2031, according to a recent study by Fairfield Market Research. The market is driven by the increasing prevalence of breast cancer, technological advancements in multigene assays, and growing awareness of the importance of early cancer recurrence screening.

Key Insights and Market Trends

The Role of 21-Gene Recurrence Score Test

The 21-gene recurrence score test is a crucial tool in predicting distant recurrence risk and guiding adjuvant treatment decisions in early-stage breast cancer patients. It helps tailor treatment plans, reducing the risk of over- or under-treatment, making it a cost-effective alternative to adjuvant chemotherapy.

Rising Breast Cancer Cases

The global burden of breast cancer continues to grow, necessitating effective screening and diagnostic procedures. In some countries, such as India, breast cancer presents more aggressive patterns, emphasizing the need for early recurrence screening and management.

Complex Impact of Patient Age and Hormone Receptor Expression

Patient age and hormone receptor expression can significantly impact the 21-gene recurrence score test results. This complexity underscores the importance of a comprehensive assessment, particularly for women under 50, to ensure accurate treatment decisions.

Country-specific Market Dynamics

United States – Rising Prevalence and Lowering Recurrence Risk

Breast cancer remains the most commonly diagnosed cancer among women in the United States. Advances in hormone therapy and adjuvant therapies have significantly reduced the risk of recurrence, making recurrence score testing crucial in tailoring treatment.

Germany – Favorable Reimbursement Policies

Germany boasts a large cancer patient pool and favorable reimbursement policies for biomarker-based recurrence score tests. Public awareness initiatives and government support contribute to market growth.

India – Aggressive Breast Cancer Patterns

Breast cancer in India tends to be more aggressive, affecting a younger population. The need for early cancer recurrence screening and better access to quality healthcare presents significant growth opportunities for market players.

Competitive Landscape

The breast recurrence score test market features several active players, both local and global. Companies are investing in research and development and expanding their offerings to meet the increasing demand for screening and diagnostic solutions.

Key Companies in the Market
• Exact Sciences (Genome Health Inc.)
• NanoString Technologies, Inc.
• Foundation Medicine, Inc
• ThermoFisher Scientific
• Illumina, Inc
• Hologic Inc (Biotheranostic)
• Biocartis
• Roche Diagnostics
• Epic Sciences
• Qiagen
• Abbott
• Myriad Genetics, Inc.
• Guardant Health

Key Segments of Breast Recurrence Score Test Industry Research

Product:
• Test Kits
• Reagents & Consumables

Indication:
• Stage 1 Breast Cancer
• Stage 2 Breast Cancer
• Estrogen-Receptor-Positive Cancer
• Lymph-Node-Negative Cancer

End User:
• Hospitals
• Specialty Cancer Centers
• Diagnostic Centers
• Cancer Research Institutions

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.